FHD-286 in Subjects With Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2025-08-29
Target enrollment:
Participant gender:
Summary
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to
assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal
Melanoma (UM).